30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Regenxbio Inc (RGNX)

Track

In the last 90 days, Regenxbio Inc. has seen two insider transactions, both sales totaling $537,079.53. Notably, Stephen Pakola and Steve Pakola, holding Officer and Chief Medical Officer titles respectively, made proposed and planned sales in May 2026. The company's stock has experienced a 2.5% decrease over the past 90 days.
Stock chart
Ticker: RGNX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
PAKOLA STEVE
Chief Medical Officer
1 sale — total 168,705 USD
Planned sale 11 May 2026
Value US$4,293,989.05 | Price 230.59 | Shares 13,387
Proposed sale 11 May 2026
Value US$4,245,352.64 | Price 133.83 | Shares 6,791
Planned sale 10 Mar 2026
Value US$53,033.40 | Price 10.35 | Shares 5,124
Proposed sale 10 Mar 2026
Value US$53,187.12 | Price 10.38 | Shares 5,124
Planned sale 9 Oct 2025
Value US$262,634.82 | Price 12.62 | Shares 20,811
Proposed sale 9 Oct 2025
Value US$254,310.42 | Price 12.22 | Shares 20,811
Planned sale 29 Sep 2025
Value US$76,468.72 | Price 10.03 | Shares 7,624
Planned sale 10 Sep 2025
Value US$77,494.68 | Price 10.02 | Shares 7,734
Proposed sale 10 Sep 2025
Value US$151,890.62 | Price 9.89 | Shares 15,358
Planned sale 12 May 2025
Value US$163,046.29 | Price 7.91 | Shares 20,602
Proposed sale 12 May 2025
Value US$154,927.04 | Price 7.52 | Shares 20,602
Proposed sale 30 Dec 2024
Value US$148,503.81 | Price 7.41 | Shares 20,041
Planned sale 1 Oct 2024
Value US$101,052.00 | Price 10.11 | Shares 10,000
Planned sale 3 Sep 2024
Value US$8,638.00 | Price 12.34 | Shares 700
Planned sale 3 Sep 2024
Value US$106,950.00 | Price 11.50 | Shares 9,300
Planned sale 1 Aug 2024
Value US$1,500.00 | Price 15.00 | Shares 100
Planned sale 1 Aug 2024
Value US$1,500.00 | Price 15.00 | Shares 100
Planned sale 1 Aug 2024
Value US$5,834.00 | Price 14.59 | Shares 400
Planned sale 1 Aug 2024
Value US$129,120.00 | Price 13.45 | Shares 9,600
Proposed sale 1 Aug 2024
Value US$441,750.00 | Price 14.25 | Shares 31,000
Planned sale 29 Jul 2024
Value US$145,105.92 | Price 15.04 | Shares 9,648
Planned sale 29 Jul 2024
Value US$165,495.00 | Price 15.05 | Shares 11,000
Proposed sale 29 Jul 2024
Value US$359,768.98 | Price 14.33 | Shares 25,106
Planned sale 25 Jul 2024
Value US$214,500.52 | Price 13.96 | Shares 15,369
Planned sale 24 Jul 2024
Value US$168,433.49 | Price 13.78 | Shares 12,221
Planned sale 17 Jul 2024
Value US$30,439.88 | Price 13.77 | Shares 2,210
Planned sale 16 Jul 2024
Value US$2,752.00 | Price 13.76 | Shares 200
Planned sale 1 Jul 2024
Value US$112,691.00 | Price 11.27 | Shares 10,000
Proposed sale 1 Jul 2024
Value US$351,000.00 | Price 11.70 | Shares 30,000
Planned sale 14 May 2024
Value US$237,222.00 | Price 15.81 | Shares 15,000
Proposed sale 14 May 2024
Value US$708,300.00 | Price 15.74 | Shares 45,000
Planned sale 15 Apr 2024
Value US$272,871.00 | Price 18.19 | Shares 15,000
Planned sale 14 Mar 2024
Value US$327,942.00 | Price 21.86 | Shares 15,000
Planned sale 5 Mar 2024
Value US$365,220.08 | Price 28.36 | Shares 12,878
Proposed sale 5 Mar 2024
Value US$275,074.08 | Price 21.36 | Shares 12,878
Planned sale 14 Feb 2024
Value US$174,722.88 | Price 16.88 | Shares 10,348
Planned sale 14 Feb 2024
Value US$76,625.88 | Price 16.47 | Shares 4,652
Planned sale 16 Jan 2024
Value US$682,992.00 | Price 15.18 | Shares 45,000
Proposed sale 16 Jan 2024
Value US$1,361,700.00 | Price 15.13 | Shares 90,000
Planned sale 3 Jan 2024
Value US$299,789.35 | Price 17.39 | Shares 17,237
Proposed sale 3 Jan 2024
Value US$316,126.58 | Price 18.34 | Shares 17,237
Planned sale 19 Dec 2023
Value US$885,825.00 | Price 19.69 | Shares 45,000
Proposed sale 19 Dec 2023
Value US$877,950.00 | Price 19.51 | Shares 45,000
Planned sale 3 Jan 2023
Value US$69,559.42 | Price 22.17 | Shares 3,138
Planned sale 30 Aug 2022
Value US$72,572.64 | Price 30.24 | Shares 2,400
Planned sale 5 Aug 2022
Value US$608,034.82 | Price 35.19 | Shares 17,280
Planned sale 4 Aug 2022
Value US$14,000.00 | Price 35.00 | Shares 400
Planned sale 1 Aug 2022
Value US$75,012.00 | Price 31.26 | Shares 2,400
Planned sale 14 Jul 2022
Value US$14,040.00 | Price 30.00 | Shares 468
Planned sale 13 Jul 2022
Value US$129,988.16 | Price 30.01 | Shares 4,332
Planned sale 3 Jan 2022
Value US$53,932.50 | Price 33.75 | Shares 1,598
Planned sale 8 Nov 2021
Value US$60,000.00 | Price 40.00 | Shares 1,500
Planned sale 27 Sep 2021
Value US$63,285.00 | Price 42.19 | Shares 1,500
Planned sale 25 Jun 2021
Value US$60,375.00 | Price 40.25 | Shares 1,500
Planned sale 24 Jun 2021
Value US$180,090.00 | Price 40.02 | Shares 4,500
Planned sale 25 Feb 2021
Value US$61,155.00 | Price 40.77 | Shares 1,500
Planned sale 12 Feb 2021
Value US$230,725.08 | Price 49.08 | Shares 4,701
Planned sale 8 Feb 2021
Value US$63,843.00 | Price 49.11 | Shares 1,300
Planned sale 2 Feb 2021
Value US$22,565.00 | Price 45.13 | Shares 500
Planned sale 2 Feb 2021
Value US$425,315.00 | Price 44.77 | Shares 9,500
Planned sale 25 Jan 2021
Value US$234,442.89 | Price 44.99 | Shares 5,211
Planned sale 25 Jan 2021
Value US$42,904.70 | Price 44.05 | Shares 974
Planned sale 25 Jan 2021
Value US$13,431.60 | Price 42.64 | Shares 315
Planned sale 15 Jan 2021
Value US$12,610.08 | Price 50.04 | Shares 252
Planned sale 14 Jan 2021
Value US$554,982.79 | Price 50.03 | Shares 11,093
Planned sale 14 Jan 2021
Value US$580,716.12 | Price 50.01 | Shares 11,612
Planned sale 12 Jan 2021
Value US$85,051.00 | Price 50.03 | Shares 1,700
Planned sale 12 Jan 2021
Value US$210,042.00 | Price 50.01 | Shares 4,200
Planned sale 12 Jan 2021
Value US$67,728.70 | Price 49.15 | Shares 1,378
Planned sale 11 Jan 2021
Value US$496,787.76 | Price 49.08 | Shares 10,122
Planned sale 8 Jan 2021
Value US$63,531.60 | Price 48.13 | Shares 1,320
Planned sale 8 Jan 2021
Value US$192,620.04 | Price 47.42 | Shares 4,062
Planned sale 8 Jan 2021
Value US$214,413.74 | Price 46.43 | Shares 4,618
Planned sale 8 Jan 2021
Value US$27,589.95 | Price 48.15 | Shares 573
Planned sale 8 Jan 2021
Value US$104,857.92 | Price 47.49 | Shares 2,208
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-13 2026-05-11 PlS Planned sale
PAKOLA STEVE

Chief Medical Officer

Officer
13,387 +27.9%
230.59
US$4,293,989 		13,387 +27.9% 230.59 US$4,293,989
2026-05-11 2026-05-11 PrS Proposed sale
STEPHEN PAKOLA

Officer

Officer
6,791
133.83
US$4,245,353 		6,791 133.83 US$4,245,353
2026-03-12 2026-03-10 PlS Planned sale
PAKOLA STEVE

Chief Medical Officer

Officer
75,460 +48.2%
455.83
US$2,089,562 		75,460 +48.2% 455.83 US$2,089,562
2026-03-10 2026-03-10 PrS Proposed sale
STEPHEN J PAKOLA

Officer

Officer
5,124
10.38
US$53,187 		5,124 10.38 US$53,187
2025-10-10 2025-10-09 PlS Planned sale
Simpson Curran

Chief Executive Officer

Executive Director
20,811 -8.8%
12.62
US$262,635 		20,811 -8.8% 12.62 US$262,635
2025-10-09 2025-10-09 PrS Proposed sale
CURRAN M SIMPSON

Director; Officer

Executive Director
20,811
12.22
US$254,310 		20,811 12.22 US$254,310
2025-10-01 2025-09-29 PlS Planned sale
Simpson Curran

Chief Executive Officer

Executive Director
7,624 -3.1%
10.03
US$76,469 		7,624 -3.1% 10.03 US$76,469
2025-09-12 2025-09-10 PlS Planned sale
Simpson Curran

Chief Executive Officer

Executive Director
7,734 -3.1%
10.02
US$77,495 		7,734 -3.1% 10.02 US$77,495
2025-09-10 2025-09-10 PrS Proposed sale
CURRAN M SIMPSON

Director; Officer

Executive Director
15,358
9.89
US$151,891 		15,358 9.89 US$151,891
2025-05-14 2025-05-12 PlS Planned sale
Mills Kenneth T.
Non-Executive Director
20,602 -4.2%
7.91
US$163,046 		20,602 -4.2% 7.91 US$163,046
2025-05-12 2025-05-12 PrS Proposed sale
KENNETH MILLS

Director

Non-Executive Director
20,602
7.52
US$154,927 		20,602 7.52 US$154,927
2024-12-30 2024-12-30 PrS Proposed sale
VITTAL VASISTA

Officer

Officer
20,041
7.41
US$148,504 		20,041 7.41 US$148,504
2024-10-02 2024-10-01 PlS Planned sale
1.6
KARABELAS ARGERIS N
Non-Executive Director
10,000 -47.0%
10.11
US$101,052 		10,000 -47.0% 10.11 US$101,052
2024-09-04 2024-09-03 PlS Planned sale
1.6
KARABELAS ARGERIS N
Non-Executive Director
700 -5.8%
12.34
US$8,638 		700 -5.8% 12.34 US$8,638
2024-09-04 2024-09-03 PlS Planned sale
1.6
KARABELAS ARGERIS N
Non-Executive Director
9,300 -43.7%
11.50
US$106,950 		9,300 -43.7% 11.50 US$106,950
2024-08-05 2024-08-01 PlS Planned sale
Simpson Curran

Chief Executive Officer

Executive Director
100 -0.1%
15.00
US$1,500 		100 -0.1% 15.00 US$1,500
2024-08-05 2024-08-01 PlS Planned sale
1.6
KARABELAS ARGERIS N
Non-Executive Director
100 -0.9%
15.00
US$1,500 		100 -0.9% 15.00 US$1,500
2024-08-05 2024-08-01 PlS Planned sale
1.6
KARABELAS ARGERIS N
Non-Executive Director
400 -3.4%
14.59
US$5,834 		400 -3.4% 14.59 US$5,834
2024-08-05 2024-08-01 PlS Planned sale
1.6
KARABELAS ARGERIS N
Non-Executive Director
9,600 -44.9%
13.45
US$129,120 		9,600 -44.9% 13.45 US$129,120
2024-08-01 2024-08-01 PrS Proposed sale
1.6
ARGERIS N KARABELAS

Director

Non-Executive Director
31,000
14.25
US$441,750 		31,000 14.25 US$441,750
2024-07-30 2024-07-29 PlS Planned sale
Simpson Curran

Chief Executive Officer

Executive Director
9,648 -5.4%
15.04
US$145,106 		9,648 -5.4% 15.04 US$145,106
2024-07-30 2024-07-29 PlS Planned sale
1.6
KARABELAS ARGERIS N
Non-Executive Director
11,000 -49.4%
15.05
US$165,495 		11,000 -49.4% 15.05 US$165,495
2024-07-29 2024-07-29 PrS Proposed sale
CURRAN M SIMPSON

Director; Officer

Executive Director
25,106
14.33
US$359,769 		25,106 14.33 US$359,769
2024-07-26 2024-07-25 PlS Planned sale
Mills Kenneth T.
Non-Executive Director
15,369 -3.6%
13.96
US$214,501 		15,369 -3.6% 13.96 US$214,501
2024-07-26 2024-07-24 PlS Planned sale
Mills Kenneth T.
Non-Executive Director
12,221 -2.9%
13.78
US$168,433 		12,221 -2.9% 13.78 US$168,433
2024-07-18 2024-07-17 PlS Planned sale
Mills Kenneth T.
Non-Executive Director
2,210 -0.5%
13.77
US$30,440 		2,210 -0.5% 13.77 US$30,440
2024-07-18 2024-07-16 PlS Planned sale
Mills Kenneth T.
Non-Executive Director
200 -0.0%
13.76
US$2,752 		200 -0.0% 13.76 US$2,752
2024-07-03 2024-07-01 PlS Planned sale
1.6
KARABELAS ARGERIS N
Non-Executive Director
10,000 -47.0%
11.27
US$112,691 		10,000 -47.0% 11.27 US$112,691
2024-07-01 2024-07-01 PrS Proposed sale
1.6
ARGERIS N KARABELAS

Director

Non-Executive Director
30,000
11.70
US$351,000 		30,000 11.70 US$351,000
2024-05-16 2024-05-14 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
15,000 -3.5%
15.81
US$237,222 		15,000 -3.5% 15.81 US$237,222
2024-05-14 2024-05-14 PrS Proposed sale
KENNETH MILLS

Director; Officer

Executive Director
45,000
15.74
US$708,300 		45,000 15.74 US$708,300
2024-04-17 2024-04-15 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
15,000 -3.5%
18.19
US$272,871 		15,000 -3.5% 18.19 US$272,871
2024-03-18 2024-03-14 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
15,000 -3.5%
21.86
US$327,942 		15,000 -3.5% 21.86 US$327,942
2024-03-07 2024-03-05 PlS Planned sale
PAKOLA STEVE

Chief Medical Officer

Officer
12,878 -10.7%
28.36
US$365,220 		12,878 -10.7% 28.36 US$365,220
2024-03-05 2024-03-05 PrS Proposed sale
STEPHEN J PAKOLA

Officer

Officer
12,878
21.36
US$275,074 		12,878 21.36 US$275,074
2024-02-16 2024-02-14 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
10,348 -2.5%
16.88
US$174,723 		10,348 -2.5% 16.88 US$174,723
2024-02-16 2024-02-14 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
4,652 -1.1%
16.47
US$76,626 		4,652 -1.1% 16.47 US$76,626
2024-01-18 2024-01-16 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
45,000 -9.9%
15.18
US$682,992 		45,000 -9.9% 15.18 US$682,992
2024-01-16 2024-01-16 PrS Proposed sale
KENNETH THOMAS MILLS

Director; Officer

Executive Director
90,000
15.13
US$1,361,700 		90,000 15.13 US$1,361,700
2024-01-04 2024-01-03 PlS Planned sale
PAKOLA STEVE

Chief Medical Officer

Officer
17,237 -13.9%
17.39
US$299,789 		17,237 -13.9% 17.39 US$299,789
2024-01-03 2024-01-03 PrS Proposed sale
STEPHEN J PAKOLA

Officer

Officer
17,237
18.34
US$316,127 		17,237 18.34 US$316,127
2023-12-21 2023-12-19 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
45,000 -11.2%
19.69
US$885,825 		45,000 -11.2% 19.69 US$885,825
2023-12-19 2023-12-19 PrS Proposed sale
KENNETH THOMAS MILLS

Director; Officer

Executive Director
45,000
19.51
US$877,950 		45,000 19.51 US$877,950
2023-01-05 2023-01-03 PlS Planned sale
PAKOLA STEVE

Chief Medical Officer

Officer
3,138 -20.5%
22.17
US$69,559 		3,138 -20.5% 22.17 US$69,559
2022-08-31 2022-08-30 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
2,400 -1.7%
30.24
US$72,573 		2,400 -1.7% 30.24 US$72,573
2022-08-08 2022-08-05 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
17,280 -11.2%
35.19
US$608,035 		17,280 -11.2% 35.19 US$608,035
2022-08-08 2022-08-04 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
400 -0.3%
35.00
US$14,000 		400 -0.3% 35.00 US$14,000
2022-08-03 2022-08-01 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
2,400 -1.5%
31.26
US$75,012 		2,400 -1.5% 31.26 US$75,012
2022-07-15 2022-07-14 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
468 -0.3%
30.00
US$14,040 		468 -0.3% 30.00 US$14,040
2022-07-15 2022-07-13 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
4,332 -2.7%
30.01
US$129,988 		4,332 -2.7% 30.01 US$129,988
2022-01-04 2022-01-03 PlS Planned sale
PAKOLA STEVE

Chief Medical Officer

Officer
1,598 -16.2%
33.75
US$53,932 		1,598 -16.2% 33.75 US$53,932
2021-11-10 2021-11-08 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
1,500 -0.5%
40.00
US$60,000 		1,500 -0.5% 40.00 US$60,000
2021-09-29 2021-09-27 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
1,500 -0.5%
42.19
US$63,285 		1,500 -0.5% 42.19 US$63,285
2021-06-28 2021-06-25 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
1,500 -0.5%
40.25
US$60,375 		1,500 -0.5% 40.25 US$60,375
2021-06-28 2021-06-24 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
4,500 -1.6%
40.02
US$180,090 		4,500 -1.6% 40.02 US$180,090
2021-03-01 2021-02-25 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
1,500 -0.5%
40.77
US$61,155 		1,500 -0.5% 40.77 US$61,155
2021-02-17 2021-02-12 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
4,701 -22.3%
49.08
US$230,725 		4,701 -22.3% 49.08 US$230,725
2021-02-10 2021-02-08 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
1,300 -7.4%
49.11
US$63,843 		1,300 -7.4% 49.11 US$63,843
2021-02-04 2021-02-02 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
500 -3.0%
45.13
US$22,565 		500 -3.0% 45.13 US$22,565
2021-02-04 2021-02-02 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
9,500 -36.0%
44.77
US$425,315 		9,500 -36.0% 44.77 US$425,315
2021-01-27 2021-01-25 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
5,211 -1.8%
44.99
US$234,443 		5,211 -1.8% 44.99 US$234,443
2021-01-27 2021-01-25 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
974 -0.3%
44.05
US$42,905 		974 -0.3% 44.05 US$42,905
2021-01-27 2021-01-25 PlS Planned sale
Mills Kenneth T.

President and CEO

Executive Director
315 -0.1%
42.64
US$13,432 		315 -0.1% 42.64 US$13,432
2021-01-20 2021-01-15 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
252 -0.2%
50.04
US$12,610 		252 -0.2% 50.04 US$12,610
2021-01-14 2021-01-14 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
11,093 -8.9%
50.03
US$554,983 		11,093 -8.9% 50.03 US$554,983
2021-01-14 2021-01-14 PlS Planned sale
Simpson Curran

Chief Oper. & Tech. Officer

Officer
11,612 -39.6%
50.01
US$580,716 		11,612 -39.6% 50.01 US$580,716
2021-01-14 2021-01-12 PlS Planned sale
Simpson Curran

Chief Oper. & Tech. Officer

Officer
1,700 -8.7%
50.03
US$85,051 		1,700 -8.7% 50.03 US$85,051
2021-01-14 2021-01-12 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
4,200 -3.3%
50.01
US$210,042 		4,200 -3.3% 50.01 US$210,042
2021-01-12 2021-01-12 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
1,378 -7.8%
49.15
US$67,729 		1,378 -7.8% 49.15 US$67,729
2021-01-12 2021-01-11 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
10,122 -38.2%
49.08
US$496,788 		10,122 -38.2% 49.08 US$496,788
2021-01-12 2021-01-08 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
1,320 -7.5%
48.13
US$63,532 		1,320 -7.5% 48.13 US$63,532
2021-01-12 2021-01-08 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
4,062 -18.7%
47.42
US$192,620 		4,062 -18.7% 47.42 US$192,620
2021-01-12 2021-01-08 PlS Planned sale
Christmas Patrick J.

Chief Legal Officer

Officer
4,618 -17.5%
46.43
US$214,414 		4,618 -17.5% 46.43 US$214,414
2021-01-11 2021-01-08 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
573 -0.4%
48.15
US$27,590 		573 -0.4% 48.15 US$27,590
2021-01-11 2021-01-08 PlS Planned sale
Vasista Vittal

Chief Financial Officer

Officer
2,208 -1.7%
47.49
US$104,858 		2,208 -1.7% 47.49 US$104,858
Explore more

More insider trading research around Regenxbio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America